Market Cap 4.06B
Revenue (ttm) 167.13M
Net Income (ttm) -4.03M
EPS (ttm) N/A
PE Ratio 97.03
Forward PE N/A
Profit Margin -2.41%
Debt to Equity Ratio 0.00
Volume 141,675
Avg Vol 204,436
Day's Range N/A - N/A
Shares Out 19.68M
Stochastic %K 4%
Beta 0.91
Analysts Strong Sell
Price Target $225.00

Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pn...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 550 7500
Address:
555 Heritage Drive, Suite 200, Jupiter, United States
PrivateProfiteering
PrivateProfiteering Nov. 21 at 4:07 AM
$LGND is currently trading at $199.03, showing a neutral to slightly bullish sentiment with an RSI of 56.92, indicating potential for upward movement without being overbought. The price is above both the 30-day moving average (MA30) of 192.61 and the 50-day moving average (MA50) of 184.95, suggesting a positive trend. The recent high of 212.49 and low of 158.4 over the past 60 days establishes a range that supports further upside potential. Suggested entry point is at $200.00, just above the current price to confirm bullish momentum. A stop loss can be placed at $192.00, below the MA30 for risk management. Target 1 is set at $210.00, near the 60D high, while Target 2 can be set at $215.00 for additional upside capture. This plan leverages the current market context and technical indicators for a calculated approach. https://privateprofiteers.com
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 20 at 9:23 AM
$LGND is currently trading at $200.86, showing a bullish market context given the RSI of 60.11, which indicates momentum without being overbought. The price is above both the 30-day moving average (MA30) at $189.91 and the 50-day moving average (MA50) at $181.96, suggesting a strong upward trend. The recent high of $212.49 and low of $156.91 over the past 60 days further supports a bullish bias, as the price is closer to the high. Suggested entry point is around $202, slightly above the last close to confirm upward momentum. Set a stop loss at $192, below the MA30, to manage risk. For targets, consider $210 as the first target, aligning with the recent high, and $215 as a second target, providing a reasonable profit-taking point. Overall, the combination of RSI, moving averages, and the high-low range indicates a favorable trading opportunity. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 19 at 11:20 PM
1ightning® Options Trade Alert (Actionable) | Buy $LGND Dec 19 $210 Call | Enter: $6.62 Exit: $9.74 | Profit: 46.95% ROI | https://1ightning.com
0 · Reply
Elevator_up
Elevator_up Nov. 19 at 11:49 AM
$VKTX $LGND Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year • good article- regarding Ligand. • would encourage those interested to track the connection with VK2809. https://www.investors.com/news/technology/ligand-pharmaceuticals-royalty-business-biotech/?gaa_at=la&gaa_n=AWEtsqdclWpJXKi3Rb6hVu1Hg7SyaRHwRLSoL7a2f4YUo8qUs-KMkigD0kv9Cnwc5d4%3D&gaa_ts=691daee8&utm_source=newsshowcase&utm_medium=discover&utm_campaign=CCwqGQgwKhAIACoHCAowzpuGCzCQ9YMDMKqx3wQwtrGZBQ&utm_content=bullets&gaa_sig=kvLVeDBy9H_SoRl__TUm2l7ssDvfiFuHQaNHmshLvGRrvynX_NCxKyaZN59BE4q1lkJSqOLWPWX4fNgJNhmHsg%3D%3D
2 · Reply
Iightning
Iightning Nov. 19 at 7:37 AM
1ightning® Options Trade Alert (Actionable) | Buy $LGND Dec 19 $210 Call | Enter: $6.62 Exit: $9.74 | Profit: 46.95% ROI | https://1ightning.com
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 14 at 5:36 PM
$LGND Share Price: $204.93 Contract Selected: May 15, 2026 $200 Calls Buy Zone: $18.27 – $22.57 Target Zone: $33.62 – $41.09 Potential Upside: 74% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 11 at 3:33 PM
Results List 11/2025 13;days to go. $LC $LGND $LLYX $LITE $LLY
0 · Reply
Doozio
Doozio Nov. 11 at 2:38 AM
With moar of that volume how $LGND $ARRY can it get during 🐒🍌🧠⏰♾️?
0 · Reply
ZacksSCR
ZacksSCR Nov. 10 at 8:07 PM
$LGND: Target Up On Improved Growth Outlook https://buff.ly/3KAJ8jQ
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 3:57 PM
RBC Capital has updated their rating for Ligand Pharmaceuticals ( $LGND ) to Outperform with a price target of 234.
0 · Reply
Latest News on LGND
Ligand to Participate in November Investor Conferences

Oct 30, 2025, 4:01 PM EDT - 21 days ago

Ligand to Participate in November Investor Conferences


Ligand to Host Investor Day on December 9, 2025

Oct 16, 2025, 7:00 AM EDT - 5 weeks ago

Ligand to Host Investor Day on December 9, 2025


Ligand to Participate in September Investor Conferences

Aug 19, 2025, 4:00 PM EDT - 3 months ago

Ligand to Participate in September Investor Conferences


Ligand Announces Closing of Convertible Senior Notes Offering

Aug 14, 2025, 4:00 PM EDT - 3 months ago

Ligand Announces Closing of Convertible Senior Notes Offering


Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Jul 10, 2025, 8:00 AM EDT - 4 months ago

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™


Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

Jun 24, 2025, 2:47 PM EDT - 5 months ago

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward


Ligand Announces 2025 Investor Day in New York City

Jun 11, 2025, 7:00 AM EDT - 5 months ago

Ligand Announces 2025 Investor Day in New York City


Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 14, 2025, 7:00 AM EDT - 6 months ago

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025


Ligand Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 7 months ago

Ligand Reports First Quarter 2025 Financial Results


Ligand to Participate in May Investor Conferences

May 1, 2025, 7:00 AM EDT - 7 months ago

Ligand to Participate in May Investor Conferences


Ligand to Participate in March Investor Conferences

Mar 3, 2025, 7:00 AM EST - 9 months ago

Ligand to Participate in March Investor Conferences


Looking Back On Ligand Pharmaceuticals

Feb 3, 2025, 2:59 PM EST - 10 months ago

Looking Back On Ligand Pharmaceuticals


Ligand to Present at Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ligand to Present at Stifel 2024 Healthcare Conference


Ligand Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Ligand Reports Second Quarter 2024 Financial Results


Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29, 2024, 2:43 PM EDT - 1 year ago

Ligand Pharmaceuticals: Solid Performer Performing Solidly


PrivateProfiteering
PrivateProfiteering Nov. 21 at 4:07 AM
$LGND is currently trading at $199.03, showing a neutral to slightly bullish sentiment with an RSI of 56.92, indicating potential for upward movement without being overbought. The price is above both the 30-day moving average (MA30) of 192.61 and the 50-day moving average (MA50) of 184.95, suggesting a positive trend. The recent high of 212.49 and low of 158.4 over the past 60 days establishes a range that supports further upside potential. Suggested entry point is at $200.00, just above the current price to confirm bullish momentum. A stop loss can be placed at $192.00, below the MA30 for risk management. Target 1 is set at $210.00, near the 60D high, while Target 2 can be set at $215.00 for additional upside capture. This plan leverages the current market context and technical indicators for a calculated approach. https://privateprofiteers.com
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 20 at 9:23 AM
$LGND is currently trading at $200.86, showing a bullish market context given the RSI of 60.11, which indicates momentum without being overbought. The price is above both the 30-day moving average (MA30) at $189.91 and the 50-day moving average (MA50) at $181.96, suggesting a strong upward trend. The recent high of $212.49 and low of $156.91 over the past 60 days further supports a bullish bias, as the price is closer to the high. Suggested entry point is around $202, slightly above the last close to confirm upward momentum. Set a stop loss at $192, below the MA30, to manage risk. For targets, consider $210 as the first target, aligning with the recent high, and $215 as a second target, providing a reasonable profit-taking point. Overall, the combination of RSI, moving averages, and the high-low range indicates a favorable trading opportunity. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 19 at 11:20 PM
1ightning® Options Trade Alert (Actionable) | Buy $LGND Dec 19 $210 Call | Enter: $6.62 Exit: $9.74 | Profit: 46.95% ROI | https://1ightning.com
0 · Reply
Elevator_up
Elevator_up Nov. 19 at 11:49 AM
$VKTX $LGND Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year • good article- regarding Ligand. • would encourage those interested to track the connection with VK2809. https://www.investors.com/news/technology/ligand-pharmaceuticals-royalty-business-biotech/?gaa_at=la&gaa_n=AWEtsqdclWpJXKi3Rb6hVu1Hg7SyaRHwRLSoL7a2f4YUo8qUs-KMkigD0kv9Cnwc5d4%3D&gaa_ts=691daee8&utm_source=newsshowcase&utm_medium=discover&utm_campaign=CCwqGQgwKhAIACoHCAowzpuGCzCQ9YMDMKqx3wQwtrGZBQ&utm_content=bullets&gaa_sig=kvLVeDBy9H_SoRl__TUm2l7ssDvfiFuHQaNHmshLvGRrvynX_NCxKyaZN59BE4q1lkJSqOLWPWX4fNgJNhmHsg%3D%3D
2 · Reply
Iightning
Iightning Nov. 19 at 7:37 AM
1ightning® Options Trade Alert (Actionable) | Buy $LGND Dec 19 $210 Call | Enter: $6.62 Exit: $9.74 | Profit: 46.95% ROI | https://1ightning.com
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 14 at 5:36 PM
$LGND Share Price: $204.93 Contract Selected: May 15, 2026 $200 Calls Buy Zone: $18.27 – $22.57 Target Zone: $33.62 – $41.09 Potential Upside: 74% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 11 at 3:33 PM
Results List 11/2025 13;days to go. $LC $LGND $LLYX $LITE $LLY
0 · Reply
Doozio
Doozio Nov. 11 at 2:38 AM
With moar of that volume how $LGND $ARRY can it get during 🐒🍌🧠⏰♾️?
0 · Reply
ZacksSCR
ZacksSCR Nov. 10 at 8:07 PM
$LGND: Target Up On Improved Growth Outlook https://buff.ly/3KAJ8jQ
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 3:57 PM
RBC Capital has updated their rating for Ligand Pharmaceuticals ( $LGND ) to Outperform with a price target of 234.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 10:15 PM
0 · Reply
topstockalerts
topstockalerts Nov. 7 at 5:07 PM
Pelthos Therapeutics Inc shares dropped after the company announced it acquired U.S. marketing rights for Xepi, a topical treatment for impetigo, from Biofrontera and Ferrer Internacional. The Durham, North Carolina-based biopharmaceutical company will pay $3.0 million to Biofrontera and $1.2 million to Ferrer upfront, with additional payments tied to commercial availability and sales milestones. The agreement also includes royalty payments on U.S. net sales. Along with the acquisition, Pelthos closed an $18 million private financing in convertible notes with existing investors, including Ligand Pharmaceuticals and a group led by Murchinson Ltd. The notes, due in November 2027, will carry an 8.5% annual interest rate and are convertible at an initial price of $34.442. Xepi is a non-fluorinated quinolone antimicrobial cream approved by the FDA in 2017 for treating impetigo in patients aged two months and older. $PTHS $LGND
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 3:44 PM
Benchmark has adjusted their stance on Ligand Pharmaceuticals ( $LGND ), setting the rating to Buy with a target price of 175 → 220.
0 · Reply
Doozio
Doozio Nov. 6 at 7:37 PM
🐒🍌🧠⏰♾️ is $LGND ary!
1 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 6:30 PM
HC Wainwright & Co. updates rating for Ligand Pharmaceuticals ( $LGND ) to Buy, target set at 206 → 231.
0 · Reply
WAJeff
WAJeff Nov. 6 at 5:23 PM
$LGND sold at $202 today, $210 5 year high
0 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 4:05 PM
$TVTX on the $LGND earnings call this morning (which were spectacular), it was mentioned FSGS sales will exceed IgAN sales.
0 · Reply
pharmde
pharmde Nov. 6 at 1:56 PM
$LGND hell yeah
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 4 at 11:09 PM
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 3:47 PM
Oppenheimer has updated their rating for Ligand Pharmaceuticals ( $LGND ) to Outperform with a price target of 250.
0 · Reply
Doozio
Doozio Nov. 2 at 5:31 PM
$SUPN thing about it getting $LGND ary wen $XBI is in $RYTM 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Nov. 1 at 6:53 PM
$TSLA $ELSA.X is gone $TLSA 3wt bahhhtom of da base and how $LGND ary and NUTX is gonna get DAVE on eps wen da 🦄👑 is leading ☝️❤️ during 🐒🍌🧠⏰♾️ ? ❤️👑🌈🦄
0 · Reply